Apobiologix News

Apobiologix Announces Participation in BBCIC Consortium

March 8, 2017

Apobiologix has joined The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) as a participating organization.

"Apobiologix supports the BBCIC's initiative to monitor biosimilars and their corresponding novel biologics for effectiveness and safety," said Steven Lydeamore, president, Apobiologix. "The expanding field of biosimilars requires a collaborative approach to research and education, and we are grateful to be part of the BBCIC's efforts."

The only research network dedicated to monitoring biosimilars, the BBCIC is collaboration of managed care organizations, integrated delivery systems, pharmacy benefit management firms, research institutions and pharmaceutical companies. The BBCIC framework applies the same scientific, analytic methods used by the FDA Sentinel initiative, a post-market surveillance system that harnesses cutting-edge distributed research network and surveillance methods to track the safety of pharmaceuticals and other therapies once they reach the market.

Apobiologix has a robust pipeline of biosimilars products. Apobiologix launched Grastofil® (filgrastim), biosimilar to Neupogen® (filgrastim), in Europe in 2014, and in Canada in 2016. The FDA is actively reviewing the applications for this biosimilar, Grastofil® (filgrastim), as well as Lapelga® (pegfilgrastim), biosimilar to Neulasta® (pegfilgrastim). The company has also developed additional biologics, including 3 therapeutics that are in clinical development: Apobiologix epoetin alfa, biosimilar for Procrit® (epoetin alfa); Apobiologix bevacizumab, biosimilar for Avastin® (bevacizumab); Apobiologix rituximab, biosimilar for Rituxan® (rituximab). Apobiologix trastuzumab, biosimilar for Herceptin® (trastuzumab) will be entering clinical development shortly.

Return to News & Events

Invention is not the only innovation.

Apobiologix logo

2400 North Commerce Parkway,
Suite 300,
Weston, Florida 33326